Bruker BioSciences Announces Filing of Definitive Proxy and Expiration of HSR Waiting Period for Planned Acquisition of Bruker B
18 January 2008 - 1:15AM
Business Wire
Bruker BioSciences Corporation (NASDAQ: BRKR) today announced that
it has filed with the Securities and Exchange Commission its
definitive proxy statement regarding the previously announced,
planned acquisition of the Bruker BioSpin group of companies. A
special meeting of Bruker BioSciences stockholders to consider and
vote upon matters relating to the proposed acquisition will be held
on February 25, 2008. Bruker BioSciences stockholders of record as
of the close of business on January 11, 2008 will be entitled to
vote at this special meeting. Moreover, the waiting period imposed
by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, for the proposed acquisition has expired on January 14,
2008. STOCKHOLDERS OF BRUKER BIOSCIENCES SHOULD READ THE DEFINITIVE
PROXY STATEMENT CAREFULLY AS IT CONTAINS IMPORTANT INFORMATION
ABOUT THE PROPOSED ACQUISITION. IN ADDITION TO RECEIVING THE
DEFINITIVE PROXY STATEMENT FROM BRUKER BIOSCIENCES BY MAIL,
STOCKHOLDERS MAY ALSO OBTAIN THE DEFINITIVE PROXY STATEMENT, AS
WELL AS OTHER PROXY MATERIALS, WITHOUT CHARGE, FROM THE SEC'S WEB
SITE AT http://www.sec.gov OR BY DIRECTING A REQUEST TO BRUKER
BIOSCIENCES CORPORATION, 40 MANNING ROAD, BILLERICA, MA 01821,
ATTN: INVESTOR RELATIONS, TEL. +1 (978) 663-3660, EXT. 1411. The
transactions described in this announcement have not yet been
consummated. Bruker Biosciences and its executive officers and
directors may be deemed to be participants in the solicitation of
proxies for the Bruker Biosciences special meeting of stockholders
to be held to approve, among other things, the issuance of shares
in the transaction. Detailed information regarding the direct and
indirect interests of Bruker BioSciences and its executive officers
and directors in the proposed transactions are included in the
proxy statement. Cautionary Statement Any statements contained in
this press release that do not describe historical facts may
constitute forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the integration of
businesses we have acquired or may acquire in the future, changing
technologies, product development and market acceptance of our
products, the cost and pricing of our products, manufacturing,
competition, dependence on collaborative partners and key
suppliers, capital spending and government funding policies,
changes in governmental regulations, intellectual property rights,
litigation, and exposure to foreign currency fluctuations. These
and other factors are identified and described in more detail in
our filings with the SEC, including, without limitation, our annual
report on Form 10-K for the year ended December 31, 2006, our most
recent quarterly reports on Form 10-Q and our current reports on
Form 8-K. We disclaim any intent or obligation to update these
forward-looking statements other than as required by law.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024